Brought to you by 
DexCom completes $22.5mm Series D financing
08 Jan 2007
Executive Summary
DexCom (glucose monitors) grossed $22.5mm with its Series D venture round to new investors Warburg Pincus (which led the round) and the Vertical Group. Also participating in the financing were existing backers Canaan Partners, Federated Kaufmann Fund, RWI Group, St. Paul Venture Capital, and Fog City Fund (an affiliate of St. Paul). Piper Jaffray acted as placement agent.
Deal Industry
- In Vitro Diagnostics
-
Medical Devices
- Diagnostic Equipment & Supplies
- Implantable Devices
- Monitoring Equipment & Devices
-
In Vitro Diagnostics
- Biosensors
- Glucose Testing
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
DexCom completes $22.5mm Series D financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice